Abstract
Genome-wide association studies (GWAS) help to identify disease-linked genetic variants, but pinpointing the most likely causal genes in GWAS loci remains challenging. Existing GWAS gene prioritization tools are powerful, but often use complex black box models trained on datasets containing unaddressed biases. Here we present CALDERA, a gene prioritization tool that achieves similar or better performance than state-of-the-art methods, but uses just 12 features and a simple logistic regression model with L1 regularization. We use a data-driven approach to construct a truth set of causal genes in 406 GWAS loci and correct for potential confounders. We demonstrate that CALDERA is well-calibrated in external datasets and prioritizes genes with expected properties, such as being mutation-intolerant (OR = 1.751 for pLI > 90%, P = 8.45x10-3). CALDERA facilitates the prioritization of potentially causal genes in GWAS loci and may help identify novel genetics-driven drug targets.
Competing Interest Statement
M.S., D.P., and S.R. have nothing to disclose. J.C.U. is an employee of Illumina. K.H. is a former employee of 23andMe, Inc. and owns 23andMe, Inc. stock options.
Funding Statement
SR discloses support for the research of this work from the German Center for Mental Health (DZPG), the European Union's Horizon program (101057454, "PsychSTRATA"), and The German Research Foundation (402170461, grant "TRR265"). DP and MS disclose support for the research of this work from The Netherlands Organization for Scientific Research (NWO Gravitation: BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology - Grant No. 024.004.012). DP discloses support for the research of this work from The European Research Council (Advanced Grant No ERC-2018-AdG GWAS2FUNC 834057) and the European Union's Horizon program (964874, "REALMENT"). KH discloses support for the research of this work from the Alexander von Humboldt Foundation. DP and SR disclose support for the research of this work from the National Institute Of Mental Health of the National Institutes of Health (Award Number: R01MH124873). The content is the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All credible set and variant-to-gene mapping data for UK Biobank traits are available at https://www.finucanelab.org/data. All other data and code required to reproduce these analyses are available on GitHub at https://github.com/kheilbron/caldera. Gencode release 44: https://www.gencodegenes.org/human/release_44.html The Mostafavi et al. 202322 Zenodo repository: https://zenodo.org/records/6618073
https://www.gencodegenes.org/human/release_44.html
